-
Ruxolitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Ruxolitinib Myelofibrosis Novartis Chikunguru. 6, 2024 -
Relugolix
Zita reAPI Indication Innovator Patent Expiry Date (The US) Relugolix Kenza yeprostate Takeda uye ASKA Ndira 24, 2024 -
Rimegepant
Zita reAPI Indication Innovator Patent Expiry Date (The US) Rimegepant Migraine musoro Biohaven Kukadzi 22, 2031 -
Relugolix 737789-87-6
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Antineoplastic Mumba -
Ribociclib 1374639-75-4
Zita reAPI Indication Innovator Patent Expiry Date (The US) Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
PharmaceuticalsJun.27, 2028 -
Rivaroxaban
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Rivaroxaban Anticoagulant Mumba TDP -
Rosuvastatin Calcium
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Rosuvastatin Calcium Hypercholesterolemia Mumba/CEP 20705 √ CEP2015-240
